Sanofi - American Depositary Shares (SNY) analyst actions
Rating and price-target actions on SNY in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the SNY overview →
3 measured SNY analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded | Press release | -0.92% | +2.02% | |
| Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines | Press release | +0.00% | +1.34% | |
| Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded | Press release | +0.38% | +0.76% |
Keep exploring
More SNY: earnings → · SEC filings → · SNY overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SYNERGY PHARMACEUTICALS (SGYP) | 803 | -0.38% | 41% |
| BioVie Inc. - Common stock (BIVI) | 798 | -0.84% | 36% |
| Cerecor, Inc (CERC) | 795 | -0.03% | 43% |
| Second Sight Medical Products, Inc. (EYES) | 788 | -0.56% | 34% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.